About Vortex Biosciences
Vortex Biosciences is a Healthcare company based in Menlo Park (United States) founded in 2012, and was acquired by EMV Capital in March 2019. Automated isolation of circulating tumor cells from blood is provided. Vortex Biosciences has raised $4.08 million across 2 funding rounds from investors including EMV Capital and EMV Capital. Vortex Biosciences offers products and services including VTX-1 Liquid Biopsy System. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its legal entity is Vortex Biosciences Inc. Its competitors include Guardant Health, Foundation Medicine and ArcherDX; 3 of its 3 listed competitors have raised funding.
Company details
Vortex Biosciences was founded in 2012 in Menlo Park, United States, within the biotechnology sector focused on diagnostics. A liquid biopsy system known as VTX-1 is offered to automate the isolation and collection of circulating tumor cells from blood samples. These cells are released from reservoirs and gathered downstream for additional assays in clinical applications. Operations center on enabling further analysis of tumor cells for medical diagnostics.
- Headquarters Menlo Park, United States
- Stage Acquired
- SectorsHealthcare
- Website vortexbiosciences.com
- Social LinkedIn
- Acquired by EMV Capital (Mar 2019)
- Legal Name Vortex Biosciences Inc.
- Total Equity Funding$4.08M (USD)
in 2 rounds
- Latest Funding Round$4.08M (USD), Seed
Jun 2023
- InvestorsEMV Capital
& 1 more
- Acquired byEMV Capital
(Mar 2019)
Products & Services of Vortex Biosciences
Vortex Biosciences offers a comprehensive portfolio of products and services, including VTX-1 Liquid Biopsy System.
Automates capture of circulating tumor cells from blood for research.
Funding Insights of Vortex Biosciences
Vortex Biosciences has successfully raised a total of $4.08M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $4.08 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.08M
- Total Rounds 2
- Last Round Seed — $4.08M
- Investors Count 2
All 2 funding rounds of Vortex Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2023 | $4.08M | Seed | – | EMV Capital | |
| May 2022 | Seed | – | – |
2 investors in total: 2 institutional.
Investors in Vortex Biosciences
Vortex Biosciences has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include EMV Capital and EMV Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
B2B-tech focused VC firm | 2018 | emvcapital.com | London, United Kingdom | |
Venture capital investments are made in deep tech and life sciences by EMV Capital. | 2013 | netscientific.net | London, United Kingdom |
Investor details for Vortex Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Vortex Biosciences
5 people are tracked at Vortex Biosciences (3 in leadership, 2 in board & advisors).
| Name | Role | Group |
|---|---|---|
Corinne Renier | Director of R&D | Leadership |
John Matthews | Vice President of Clinical Operations | Leadership |
Chris Howie | Head of Sales | Leadership |
Ilian Iliev | Chairman & Board Member | Board & advisors |
Kevin Dean | Advisor | Board & advisors |
Complete people profiles for Vortex Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Vortex Biosciences
4 dated milestones of Vortex Biosciences across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Vortex Biosciences is founded.
- Exit Acquired by EMV Capital.
- Funding First funding round.
- Funding Latest funding round, Seed, of $4.1M.
Competitors of Vortex Biosciences
Vortex Biosciences has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, Foundation Medicine and ArcherDX.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. |
Detailed competitors of Vortex Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Vortex Biosciences (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vortex Biosciences
Complete news archive for Vortex Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vortex Biosciences
Vortex Biosciences was founded in 2012 and raised its 1st funding round 10 years after it was founded.
Vortex Biosciences is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Vortex Biosciences is a funded company, having raised a total of $4.08M across 2 funding rounds to date.
Vortex Biosciences was founded in 2012 in Menlo Park, United States, within the biotechnology sector focused on diagnostics. A liquid biopsy system known as VTX-1 is offered to automate the isolation and collection of circulating tumor cells from blood samples. These cells are released from reservoirs and gathered downstream for additional assays in clinical applications. Operations center on enabling further analysis of tumor cells for medical diagnostics.
Vortex Biosciences's top competitors include Guardant Health, Foundation Medicine and ArcherDX.
Vortex Biosciences offers VTX-1 Liquid Biopsy System.
Vortex Biosciences has 2 investors. Key investors include EMV Capital, and EMV Capital.
Vortex Biosciences operates through Vortex Biosciences Inc..
Yes. Vortex Biosciences was acquired by EMV Capital in March 2019.